| Literature DB >> 31973742 |
Signe Eekholm1,2, Gerd Ahlström3, Jimmie Kristensson4, Tove Lindhardt5.
Abstract
BACKGROUND: Community acquired pneumonia (CAP) remains a significant cause of morbidity and in-hospital mortality, and readmission rates are rising for older persons (> 65 years). Optimized treatment and nursing care will benefit patients and the health economy. Hence, there is a need to describe gaps between current clinical practice and recommendations in evidence-based guidelines for diagnostic procedures, medical treatment and nursing interventions for older patients with CAP.Entities:
Keywords: Adherence; Community acquired pneumonia; Diagnosis; Evidence-based guidelines; Treatment, Nursing care
Mesh:
Substances:
Year: 2020 PMID: 31973742 PMCID: PMC6979078 DOI: 10.1186/s12879-019-4742-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow charge of included patients
Characteristics of patients with CAP at admission to hospital (n = 30)
| Diagnostic characteristics | Frequency, n (%) or |
|---|---|
| Gender/male, | 16 (53.3) |
| Age, | |
| Smokers | 5 (16.7) |
| Penicillin allergy | 1 (3.3) |
| Cumulated Ambulation Score (CAS) < 6 | 10 (33.3) |
| Charlson Comorbidity Index (CCI), | |
| Nutritional deficiencies, | 23 (76.7) |
| Fever (≥38 °C) | 13 (43.3) |
| C-reactive protein (> 10 mg/L) | 28 (93.3) |
| Sputum production | 25 (83.3) |
| Dyspnoea | 26 (86.7) |
| Chills | 4 (13.3) |
| Pleuritic chest pain | 3 (10.0) |
| Confusion | 7 (23.3) |
| Pulse rate > 100 | 13 (43.3) |
| Respiratory rate ≥ 30 breaths/min | 4 (13.3) |
| Cough | 25 (83.3) |
| CURB-65 score: 0–1 points | 9 (30.0) |
| CURB-65 score: 2 points | 13 (43.3) |
| CURB-65 score: ≥3 points | 8 (26.7) |
| Recent travel (≤2 weeks) | 3 (10.0) |
| Responding to treatment ≤48 h | 20 (71.4)a |
| Length of hospital stay, | |
| In-hospital mortality | 3 (10.0) |
| Readmission ≤1 month | 11 (40.7)b |
| Post discharge mortality ≤1 month | 2 (7.4)b |
aAdjusted for 2 patients who were discharged ≤24 h of admission
bAdjusted for in-hospital mortality on 27 patients
CCI = Charlson Comorbidity Index is calculated based on 19 predefined comorbidities with assigned weights of 1, 2, 3, or 6 and summed to the total CCI score. CAS=Cumulated Ambulation Score is calculated by assessing 3 activities (1. getting in and out of bed, 2. sitting down and standing up from a chair, 3. walking ability with or without a walking aid) on a three-point scale
(2 = independent of human assistance or guidance, 1 = requiring human assistance or guidance to perform activity, 0 = unable to perform activity despite human assistance). The score for each activity is cumulated to provide a daily range from 0 to 6. CAS score < 6 indicates dependent of human assistance. CURB-65 = severity assessment score is calculated by giving 1 point for each of the following prognostic features: Confusion, Urea>7 mmol/l, Respiratory rate >30 breaths/minute, Low systolic (<90 mmHg) or diastolic (<60 mmHg) blood pressure, ≥65 years. The total sum is stratified for CAP severity: (score 0–1) low severity; (score 2) moderate severity; (score 3–5) high severity
HPs’ adherence to diagnostic tests regarding EBG criteria for patients with CAP
| Diagnostic tests and tests for non-responding patients | Patients n | Exposed for test, n (%) |
|---|---|---|
| Diagnostic tests: | ||
| Chest radiography | 30 | 28 (93.3) |
| Sputum test for culture and sensitivity | 25 | 19 (76.0)a |
| Chest examination (auscultation/percussion) | 30 | 30 (100.0) |
| Oxygen saturation | 30 | 30 (100.0) |
| Mini mental test | 30 | 30 (100.0) |
| Travel exposure anamnesis | 13 | 7 (53.8)b |
| Blood tests: | ||
| Blood cultures | 30 | 26 (86.7) |
| Full blood count | 30 | 30 (100.0) |
| C-reactive protein | 30 | 30 (100.0) |
| Electrolytes | 30 | 30 (100.0) |
| Liver function | 30 | 30 (100.0) |
| Arterial blood gases | 26 | 24 (92.3)c |
| Appliance of CURB-65 score to assess disease severity | 30 | 5 (16.7) |
| Non-responding to treatment ≤48 h | 28 | 8 (28.6)d |
| Tests for non-responding patients: | ||
| L. pneumophila urine antigen test, LUT | 8 | 1 (12.5) |
| Pneumococcal urine antigen test, PUT | 8 | 1 (12.5) |
| Polymerase chain reaction test, PCR | 8 | 3 (37.5) |
| Sputum test for culture and sensitivity | 8 | 1 (12.5) |
| C-reactive protein and white cell count | 8 | 8 (100.0) |
| Chest radiography | 8 | 7 (87.5) |
| Blood cultures | 8 | 7 (87.5) |
aAdjusted for patients with sputum
bAdjusted for patients not able to travel
cAdjusted for patients with SpO2 < 92%, RF > 20 or dyspnoea
dAdjusted for patients who were discharged ≤24 h of admission
HPs’ adherence to antibiotic treatment and discharge management regarding EBG criteria
| Antibiotic treatment and discharge management | Patients n | Adherence |
|---|---|---|
| Antibiotic (AB) treatment | ||
| Time (minutes) to AB prescription, | 30 | |
| Time (minutes) to AB administration, | 30 | |
| AB treatment prescribed in accordance with EBG criteria, n (%) | 30 | 4 (13.3) |
| Adjustment of AB treatment ≤48 h of admission, n (%) | 28 | 22 (78.6)a |
| Switch from intravenous to oral AB treatment in accordance with EBG criteria, n (%) | 20 | 15 (75.0)b |
| Discharge management | ||
| Prescription of 6 weeks polyclinical control, n (%) | 27 | 21 (77.8)c |
| Prescription of chest radiography (≤6 weeks post-discharge), n (%) | 27 | 6 (22.2)c |
aAdjusted for patients who were discharged ≤24 h of admission
bAdjusted for patients who responded to treatment ≤48 h (n = 20)
cAdjusted for in-hospital mortality (n = 27 surviving patients)
HPs’ adherence to EBG recommendations for general management in three medical units*
| General management | Observation day 1, Patients in need / Patients receiving treatment, n/n (%) | Observation day 2, Patients in need / Patients receiving treatment, n/n (%) | Observation day 3, Patients in need / Patients receiving treatment, n/n (%) |
|---|---|---|---|
| Sputum mobilisation | |||
| In need of sputum mobilisation | 15/11 (73.3) | 13/10 (76.9) | 9/7 (77.8) |
| Sputum mobilisation received by PEP | 11/2 (18.2) | 10/2 (20.0) | 7/3 (42.9) |
| Oral care | |||
| Oral care (twice a day) | 15/4 (26.7) | 13/3 (23.1) | 9/5 (55.6) |
| Intravenous fluid therapy | |||
| In need of fluid therapy | 15/10 (66.7) | 13/9 (69.2) | 9/7 (77.8) |
| Fluid therapy plan developed | 10/9 (90.0) | 9/8 (88.9) | 7/6 (85.7) |
| Fluids received accordance to fluid therapy plan | 9/4 (44.4) | 8/2 (25.0) | 6/4 (66.7) |
| Nutrition support | |||
| Screening for nutrition status (≤24 h) | 15/4 (26.7) | 13/4(30.8) | 9/4 (44.4) |
| Screening for nutrition status (up to or during observation days) | 15/ 8 (53.3) | 13/8 (61.5) | 9/8 (88.9) |
| In need of nutrition support | 15/11 (73.3) | 13/9 (69.2) | 9/7 (77.8) |
| Development of nutrition support pland, b | 11/6 (54.5) | 9/6 (66.7) | 7/6 (85.7) |
| Mobilization | |||
| Mobilization (walk or sit out of bed ≥20 min) | 15/11 (73.3) | 13/8 (61.5) | 9/5 (55.6) |
| In need of mobilisation support | 15/10 (66.7) | 13/10 (76.9) | 9/8 (88.9) |
| Development of mobilisation plane, b | 10/6 (60.0) | 10/7 (70.0) | 8/6 (75.0) |
| Mobilization received accordance to mobilisation plane | 6/2 (33.3) | 7/3 (42.9) | 6/3(50.0) |
| Oxygen therapy | |||
| In need of oxygen therapy | 15/9 (60.0) | 13/9 (69.2) | 9/8 (88.9) |
| Oxygen therapy initiated and monitored according to SpO2 levela | 9/8 (88.9) | 9/9 (100.0) | 8/8 (100.0) |
aOverall, 15 patients were observed day 1, 13 patients day 2 and 9 patients day 3. Results are expressed as a number of patients expected to receive the intervention and the number of patients who received it
a-eTest is adjusted for patients in need of: a) oxygen therapy; b) sputum mobilisation; c) intravenous fluid therapy; d) nutrition support; e) mobilisation plan
bCare plan was not developed according to EBG but was accepted because it described some sort of plan for patient, although incomplete and unsystematic